Anti-PAX8 (paired box gene 8) antibodies for immunohistochemistry (IHC) are widely used in diagnostic endocrine pathology. PAX8 is a lineage-associated nuclear transcription factor essential for thyroid follicular epithelial differentiation and is expressed in many thyroid neoplasms, including poorly differentiated thyroid carcinomas and a substantial subset of anaplastic thyroid carcinomas, although expression may be lost in a significant proportion of high-grade tumors depending on tumor biology and antibody clone used.

Biological significance of PAX8

PAX8 is required for thyroid follicular cell differentiation during embryonic development. Genetic disruption of Pax8 in murine models prevents formation of normal thyroid follicular cells, establishing PAX8 as a core determinant of follicular lineage specification.

In the adult thyroid, PAX8 contributes to maintenance of the differentiated follicular phenotype by regulating thyroid-specific gene expression programs, including genes involved in hormone biosynthesis and epithelial identity. Persistence of nuclear PAX8 protein expression in some high-grade thyroid carcinomas is consistent with, but does not mechanistically prove, this role in lineage maintenance, particularly in cases where other differentiation markers are reduced.

Diagnostic utility in thyroid pathology

In routine surgical pathology practice, PAX8 IHC is used as a marker of thyroid follicular epithelial origin in both primary tumors and metastatic lesions. Large multi-tumor studies demonstrate high overall rates of nuclear PAX8 positivity across thyroid carcinomas, supporting its utility in tissue-of-origin assignment.

Importantly, PAX8 expression can be retained in a subset of anaplastic thyroid carcinomas, with reported positivity rates ranging from approximately 50–75% depending on cohort size, tumor sampling, and antibody clone. This retention can assist in distinguishing anaplastic thyroid carcinoma from morphologic mimics such as squamous cell carcinoma of the head and neck, particularly when interpreted within a broader immunohistochemical panel.

In metastatic diagnostic workflows, combined interpretation of PAX8 with markers such as TTF-1 and Napsin A is useful in separating primary lung adenocarcinoma—which is typically PAX8-negative, with rare reported exceptions—from metastases of thyroid or other PAX8-positive primary tumors.

Diagnostic utility in parathyroid pathology

PAX8 expression in parathyroid tissue is antibody-dependent and variable. Comparative immunohistochemical studies demonstrate that staining patterns differ between monoclonal and polyclonal PAX8 reagents.

In particular, monoclonal PAX8 clone MRQ-50 does not label normal parathyroid tissue but may show nuclear positivity in a subset of parathyroid proliferative lesions, including hyperplasia and adenoma, while also labeling adjacent thyroid tissue.

These findings highlight the potential diagnostic value of PAX8 in selected contexts, as well as the necessity of panel-based interpretation alongside established parathyroid lineage markers such as parathyroid hormone (PTH) and GATA3.

Key performance features relevant to Anti-PAX8 CE/IVD antibodies (IHC)

Peer-reviewed IHC studies consistently describe several practical attributes relevant to clinical use of Anti-PAX8 antibodies in formalin-fixed, paraffin-embedded (FFPE) tissues:

• Nuclear localization, enabling clear scoring and improved interpretability in routine histologic sections.

• High diagnostic sensitivity for thyroid follicular lineage across multiple tumor contexts, including primary and metastatic disease, when appropriately validated.

• Clone- and epitope-dependent specificity, with published analyses demonstrating that some polyclonal or N-terminal PAX8 reagents may cross-react with other PAX family proteins (notably PAX5), creating interpretive pitfalls in lymphoid-rich tissues. This underscores the importance of careful reagent selection, validation, and contextual interpretation in clinical IHC practice.